分化型甲状腺癌患者^131I治疗前停服左旋甲状腺激素后血脂、血压与甲状腺功能的相关性分析被引量：4

Analysis of the correlations between blood lipid,blood pressure and thyroid function in patients with differentiated thyroid carcinoma after the withdrawal of L-T4 and before ^131I treatment

在线阅读下载PDF

导出

摘要目的探讨分化型甲状腺癌(DTC)患者131I治疗前停服左旋甲状腺激素(L-T4)后血脂、血压与甲状腺功能的相关性。方法回顾性分析云南省肿瘤医院116例DTC患者停服L-T4前后的甲状腺功能与血脂、血压的相关性。结果停药后甲减组三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(CHOL)、载脂蛋白B(ApoB)及舒张压(DBP)均高于停药前正常组,甲减组载脂蛋白A/载脂蛋白B(ApoA/ApoB)低于正常组(P<0.05)。甲减组高血压患病率(42.2%)高于正常组(29.3%)(P=0.040)。甲减组与正常组促甲状腺素(TSH)水平与各血脂及血压指标间均无明显相关性(P>0.05)。停药后甲减组患者分为TSH<50μIU/ml组和TSH≥50μIU/ml组,两组的血脂、血压水平及高血压患病率比较,差异均无统计学意义(P>0.05)。结论DTC患者131I治疗前停服L-T4后发生甲状腺功能减退时血脂及血压均发生异常,甲状腺功能减退达一定程度后血脂及血压变化不大。 Objective To investigate the correlations between blood lipid(BL),blood pressure(BP)and thyroid function in the patients with differentiated thyroid carcinoma(DTC)after the withdrawal of L-T4 and before 131I treatment.Methods The correlations between BL,BP and thyroid function before and after the withdrawal of L-T4 from 116 patients with DTC in Yunnan Cancer Hospital were analyzed retrospectively.Results After drug withdrawal,the levels of triglyceride(TG),low density lipoprotein cholesterol(LDL-C),total cholesterol(CHOL),apolipoprotein B(ApoB)and diastolic blood pressure(DBP)in the hypothyroidism group were all higher than those in the normal group before drug withdrawal,and the levels of the apolipoprotein A/apolipoprotein B(ApoA/ApoB)in the hypothyroidism group were lower than those in the normal group(P<0.05).The prevalence of hypertension in the hypothyroidism group(42.2%)was higher than that in the normal group(29.3%)(P=0.040).There were no significant correlations between the TSH level and the indices of BL and BP in both the hypothyroidism group and the normal group(P>0.05).After drug withdrawal,the patients with hypothyroidism were divided into the TSH<50μIU/ml group and the TSH≥50μIU/ml group.The results showed that there were no statistically significant differences in the levels of BL and BP and the prevalence of hypertension between the two groups(P>0.05).Conclusion After the withdrawal of L-T4 and before 131I treatment,DTC patients exhibit abnormal BL and BP when hypothyroidism occurs.No significant change in BL and BP after hypothyroidism reached a certain degree.

作者李浩宇刘超侯飞刀钰洋王昀邓智勇 LI Haoyu;LIU Chao;HOU Fei;DAO Yuyang;WANG Yun;DENG Zhiyong(Department of Nuclear Medicine,Yunnan Cancer Hospital,Yunnan,Kunming 650118,China)

机构地区云南省肿瘤医院核医学科

出处《中国医药科学》 2021年第4期1-4,共4页 China Medicine And Pharmacy

基金国家自然科学基金(81860312 81960322) 云南省科技计划项目(昆医联合专项)[2018FE001(-247)] 昆明医科大学研究生创新基金(2020S218)。

关键词分化型甲状腺癌甲状腺功能减退血脂血压 Differentiated thyroid carcinoma Hypothyroidism Blood lipid Blood pressure

分类号 R736.1 [医药卫生—肿瘤]

作者简介通讯作者:邓智勇。

引文网络
相关文献

参考文献1

1刘新峰,李娇,赵腾,侯敏,李慧,梁军,林岩松.刺激性甲状腺球蛋白<10ng/ml的分化型甲状腺癌^(131)I治疗后的临床转归[J].中国医学科学院学报,2016,38(1):88-92. 被引量：10

二级参考文献14

1National Cancer Institute. SEER cancer statistics factsheets:thyroid cancer.[EB/OL].[2015-04-25].
2Tuttle RM,Leboeuf R. Follow up approaches in thyroid cancer:a risk adapted paradigm[J]. Endocrinol Metab Clin North Am,2008,37(2):419-435.
3Mazzaferri EL,Robbins RJ,Spencer CA,et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma[J]. J Clin Endocrinol Metab,2003,88(4):1433-1441.
4Eustatia-Rutten CFA,Smit JWA,Romijn JA,et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma,a structured meta-analysis[J]. Clin Endocrinol,2004,61(1):61-74.
5González C,Aulinas A,Colom C,et al. Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differentiated thyroid carcinoma[J]. Clin Endocrinol,2014,80(2):301-306.
6Kim H,Kim SJ,Kim IJ,et al. Limited clinical value of periablative changes of serum markers in the prediction of biochemical remission in patients with papillary thyroid cancer[J]. Nucl Med Mol Imaging,2013,47(4):268-272.
7Ciappuccini R,Hardouin J,Heutte N,et al. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer:the impact of treatment preparation modalities and tumor burden[J]. Eur J Endocrinol,2014,171(2):247-252.
8Diaz RE,Veliz J,Wohllk N. Preablative serum thyroglobulin as predictor of disease-free survival in differentiated thyroid cancer[J]. Rev Med Chile,2013,141(12):1506-1511.
9Tuttle RM. Risk-adapted management of thyroid cancer[J]. Endocr Pract,2008,14(6):764-774.
10Tuttle RM,Tala H,Shah J,et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation:using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system[J]. Thyroid,2010,20(12):1341-1349.